Resistin hormone in diabetic kidney disease and its relation to iron status and hepcidin.

BACKGROUND

Resistin, a potent adipocyte-secreted hormone, may contribute to and modulate iron status and hepcidin level in patients with non-insulin-dependent diabetes mellitus (NIDDM) and end-stage renal disease (ESRD).

CONTEXT

The cross-sectional study aimed to determine the possible role of resistin in the iron status pathway in patients with NIDDM and ESRD events are sparse with conflicting results.

METHODS

A total of 130 patients and 42 healthy subjects were included in the study and grouped into four none obese groups with normal C-reactive protein (CRP) level: Group 1 (control), Group 2 (NIDDM), Group 3 (ESRD on hemodialysis), and Group 4 (NIDDM + ESRD on hemodialysis). Resistin hormone, ferritin, hepcidin, serum iron, TIBC, and TS% were estimated.

RESULTS

Resistin, hepcidin, and ferritin were significantly increased in all groups when compared to control. TIBC significantly increased in ESRD and NIDDM + ESRD when compared to controls. Serum iron and TS% significantly decreased in all groups when compared to controls. Resistin showed a significant positive correlation with hepcidin and ferritin.

CONCLUSION

It was determined that serum resistin elevated in patients and correlated directly with hepcidin and ferritin levels. The present finding regarding receiver-operating characteristic curve (ROC curve) analysis of resistin hormone proposed that resistin could be represented as a biomarker for iron dysfunction in NIDDM and ESRD.